ETIDIOH - NEW

  Arch Virol HU Y, Hu C, Su J, Zhu B, et al Two cross-neutralizing antibodies isolated from a COVID-19 convalescent via single B cell sorting. Arch Virol. 2025;170:199. PubMed           Abstract available Biochemistry ADEWOYE A, Ezeigbo E, Vo QH, Legleiter J, et al Amyloidogenic SARS-CoV-2 Spike Protein-Derived Peptides Form Oligomers and Selectively Damage Lipid Membranes. Biochemistry. 2025;64:3610-3622. PubMed           Abstract available Epidemiol Infect PARRADO R, Cuba-Grandy CX, Fuentes-Luppichini E, Torrico Villarroel NG, et al Multiplex RT-qPCR strategy for SARS-CoV-2 variants detection in developing countries without ngs: The Bolivian experience. Epidemiol Infect. 2025;153:e94. PubMed           Abstract available BUBAR K, Middleton C, Larremore D, Gostic K, et al A fundamental limit to the effectiveness of traveller screening with molecular tests. Epidemi...

  Abstract Highly Pathogenic Avian Influenza (HPAI) is a prominent candidate for a future human pandemic arising from a zoonotic spillover event . Its best-known subtype is H5N1 , with South- or South-East Asia a likely location for an initial outbreak. Such an outbreak would be initiated through a primary event of bird-to-human infection, followed by sustained human-to-human transmission . Early interventions require the extraction, integration and interpretation of epidemiological information from the limited and noisy case data available at outbreak onset. We studied the implications of a potential zoonotic spillover of H5N1 influenza into humans . Our simulations used BharatSim , an agent-based model framework designed primarily for the population of India , but which can be tuned easily for others. We considered a synthetic population representing primary contacts in an outbreak site with infected birds. These primary contacts transfer infections to secondary ( household) cont...

  Antiviral Res GUAN S, Wang Q, Nie J, Yao X, et al Optimization of the monoclonal antibody 3E1 through W32I mutation enhances antiviral efficacy against influenza virus subtypes H1N1 and H3N2. Antiviral Res. 2025;242:106260. PubMed           Abstract available Biochem Biophys Res Commun GABELMANN A, Biesel A, Loretz B, Lehr CM, et al Exploring the future of mRNA delivery: Beyond lipid nanoparticles. Biochem Biophys Res Commun. 2025;778:152347. PubMed           Abstract available Biochemistry SUBRAMANIAM S, Saville JW, Feng F, Freiburger L, et al Therapeutic Antibodies for Infectious Diseases: Recent Past, Present, and Future. Biochemistry. 2025;64:3487-3494. PubMed           Abstract available Epidemiol Infect CHOI H, Hwang M, Coppin JD, Chatterjee P, et al Penetration of SARS-CoV-2 Alpha, Delta, and Omicron variants in the United States. Epidemiol Infect. 2025;1...

  Highlights -- Higher Mortality in COVID-19 ECMO Patients : COVID-19 patients on ECMO had a significantly higher in-hospital mortality rate (52%) compared to H1N1 patients (6%) (p < 0.0001). -- Increased Complications in COVID-19 : COVID-19 patients had a higher incidence of complications, including: •  Secondary bloodstream infections (OR = 14.3; p = 0.003) •  Neurological complications •  Acute kidney injury requiring renal replacement therapy (RRT) -- Longer ECMO Duration in COVID-19 : COVID-19 patients required longer durations of ECMO support compared to H1N1 patients. -- Age and Comorbidities Impact Mortality : Even after adjusting for age, BMI, gender, and ECMO duration, COVID-19 conferred a 16-fold higher risk of mortality compared to H1N1 (adjusted OR = 16.8). Abstract Background Veno-venous Extracorporeal Membrane Oxygenation (V-V ECMO) in management of refractory respiratory failure due to viral respiratory infections has increased with recent pandemic...

  Antiviral Res AL KRAD D, Stegmann KM, Dickmanns A, Kumar P, et al The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication. Antiviral Res. 2025 Jul 29:106247. doi: 10.1016/j.antiviral.2025.106247. PubMed           Abstract available PATEL D, De R, Azadi N, Lee S, et al Discovery of broad-spectrum antivirals targeting viral proteases using in silico structural modeling and cellular analysis. Antiviral Res. 2025;241:106245. PubMed           Abstract available LEBEDIN M, Petrovsky N, Tabynov K, Tabynov K, et al SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody. Antiviral Res. 2025;241:106235. PubMed           Abstract available Arch Virol FERNANDEZ-ROJAS MA, Salazar AM, Ostrosky-Wegman P, Flisser A, et al A feedback loop between DNA damage, genomic ins...

  Abstract In an effort to avert future pandemics, surveillance studies aimed at identifying zoonotic viruses at high risk of spilling over into humans act to monitor the "viral chatter" at the animal-human interface. These studies are hampered, however, by the diversity of zoonotic viruses and the limited tools available to assess pandemic risk. Methods currently in use include the characterization of candidate viruses using in vitro laboratory assays and experimental transmission studies in animal models. However, transmission experiments yield relatively low-resolution outputs that are not immediately translatable to projections of viral dynamics at the level of a host population. To address this gap, we present an analytical framework to extend the use of measurements from experimental transmission studies to generate more quantitative risk assessments. Specifically, we use within-host viral titer data from index and contact animals to estimate parameters relevant to tran...

  Antimicrob Agents Chemother HARFOOT R, Lawley B, Hernandez LC, Kuang J, et al Synthetic host defense peptide inhibits SARS-CoV-2 replication in vitro. Antimicrob Agents Chemother. 2025;69:e0170024. PubMed           Abstract available TATE M, Illingworth CJR, MacGregor G, Cunningham L, et al Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial. Antimicrob Agents Chemother. 2025;69:e0005425. PubMed           Abstract available ZHOU Y, Meng X, Li J, Zeng G, et al Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants. Antimicrob Agents Chemother. 2025;69:e0056825. PubMed           Abstract available GOMI S, Price E, Burgoyne H, Faozia S, et al Omadacycline exhibits anti-inflammatory properties a...